doi:10.1016/j.tjnut.2025.06.026 Akhi R, Lavrinienko A, Hakula M, et al
In terms of their benefit in treating cardiovascular disease, we await the outcomes of new clinical trials
A vendors use of GLP-3 peptide does not create a legitimate approved category or make an experimental product equivalent to the material used in a clinical trial
The first is empirical and, unusually for a The verb in this articles title deserves scrutiny before anything else, because it carries more weight than the evidence can bear
Tirzepatide is the strongest approved option, with about a 50% placebo-adjusted liver-fat reduction in the non-diabetic SURMOUNT-J MRI data and a similar directional signal in T2D MRI data
Tinnitus may go away within days or be a permanent issue